Naturally occurring neomorphic PIK3R1 mutations activate the MAPK pathway, dictating therapeutic response to MAPK pathway inhibitors

Cancer Cell

Volumn 26, Issue 4, 2014, Pages 479-494

  Cheung, LydiaW T ^a   Yu, Shuangxing ^a   Zhang, Dong ^a   Li, Jie ^a   Ng, PatrickK S ^a   Panupinthu, Nattapon ^a,b   Mitra, Shreya ^a   Ju, Zhenlin ^a   Yu, Qinghua ^a   Liang, Han ^a   Hawke, DavidH ^a   Lu, Yiling ^a   Broaddus, RussellR ^a   Mills, GordonB ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b Mahidol University ^*  (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; 2 (4 HYDROXYPHENYL) 4 MORPHOLINOPYRIDO[3',2':4,5]FURO[3,2 D]PYRIMIDINE; 8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; GUANOSINE TRIPHOSPHATASE; HYPOTHEMYCIN; INTERLEUKIN 3; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE 7; MIXED LINEAGE KINASE 3; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; PICTILISIB; PIK3R1 PROTEIN; PROTEIN; PROTEIN CDC42; RAC1 PROTEIN; SELUMETINIB; STRESS ACTIVATED PROTEIN KINASE; STRESS ACTIVATED PROTEIN KINASE INHIBITOR; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; PHOSPHATIDYLINOSITOL 3 KINASE; PIK3R1 PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL DEATH; CELL FRACTIONATION; CELL PROLIFERATION; CELL VIABILITY; COMPLEX FORMATION; CONTROLLED STUDY; CYTOTOXICITY; DNA FRAGMENTATION; DRUG SENSITIVITY; GEL FILTRATION; GENE MUTATION; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR SPACE; MOUSE; NONHUMAN; NUCLEAR LOCALIZATION SIGNAL; PROTEIN LOCALIZATION; PROTEIN MICROARRAY; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; STABLE EXPRESSION; WESTERN BLOTTING; CELL NUCLEUS; DRUG EFFECTS; ENZYME ACTIVATION; GENETICS; HUMAN; METABOLISM; MUTATION; PHOSPHORYLATION; PROTEIN TRANSPORT;

ANTINEOPLASTIC AGENTS; CELL NUCLEUS; ENZYME ACTIVATION; HUMANS; MAP KINASE SIGNALING SYSTEM; MUTATION; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PROTEIN TRANSPORT;

EID: 84907967403     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccell.2014.08.017     Document Type: Article

References (43)

1. Ahmed I., Calle Y., Sayed M.A., Kamal J.M., Rengaswamy P., Manser E., Meiners S., Nur-E-Kamal A. Cdc42-dependent nuclear translocation of non-receptor tyrosine kinase, ACK. Biochem. Biophys. Res. Commun. 2004, 314:571-579.
2. Bachelot C., Rameh L., Parsons T., Cantley L.C. Association of phosphatidylinositol 3-kinase, via the SH2 domains of p85, with focal adhesion kinase in polyoma middle t-transformed fibroblasts. Biochim. Biophys. Acta 1996, 1311:45-52.
3. Buongiorno P., Pethe V.V., Charames G.S., Esufali S., Bapat B. Rac1 GTPase and the Rac1 exchange factor Tiam1 associate with Wnt-responsive promoters to enhance beta-catenin/TCF-dependent transcription in colorectal cancer cells. Mol. Cancer 2008, 7:73.
4. Cerami E., Gao J., Dogrusoz U., Gross B.E., Sumer S.O., Aksoy B.A., Jacobsen A., Byrne C.J., Heuer M.L., Larsson E., et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2012, 2:401-404.
5. Chadee D.N., Kyriakis J.M. MLK3 is required for mitogen activation of B-Raf, ERK and cell proliferation. Nat. Cell Biol. 2004, 6:770-776.
6. Chamberlain M.D., Berry T.R., Pastor M.C., Anderson D.H. The p85alpha subunit of phosphatidylinositol 3'-kinase binds to and stimulates the GTPase activity of Rab proteins. J.Biol. Chem. 2004, 279:48607-48614.
7. Chen L.L., Trent J.C., Wu E.F., Fuller G.N., Ramdas L., Zhang W., Raymond A.K., Prieto V.G., Oyedeji C.O., Hunt K.K., et al. A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors. Cancer Res. 2004, 64:5913-5919.
8. Cheung L.W., Hennessy B.T., Li J., Yu S., Myers A.P., Djordjevic B., Lu Y., Stemke-Hale K., Dyer M.D., Zhang F., et al. High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability. Cancer Discov 2011, 1:170-185.
9. Cuevas B.D., Lu Y., Mao M., Zhang J., LaPushin R., Siminovitch K., Mills G.B. Tyrosine phosphorylation of p85 relieves its inhibitory activity on phosphatidylinositol 3-kinase. J.Biol. Chem. 2001, 276:27455-27461.
10. Dérijard B., Raingeaud J., Barrett T., Wu I.H., Han J., Ulevitch R.J., Davis R.J. Independent human MAP-kinase signal transduction pathways defined by MEK and MKK isoforms. Science 1995, 267:682-685.
11. Dhanasekaran D.N., Reddy E.P. JNK signaling in apoptosis. Oncogene 2008, 27:6245-6251.
12. Dickens M., Rogers J.S., Cavanagh J., Raitano A., Xia Z., Halpern J.R., Greenberg M.E., Sawyers C.L., Davis R.J. A cytoplasmic inhibitor of the JNK signal transduction pathway. Science 1997, 277:693-696.
13. Etienne-Manneville S., Hall A. Rho GTPases in cell biology. Nature 2002, 420:629-635.
14. Gallo K.A., Johnson G.L. Mixed-lineage kinase control of JNK and p38 MAPK pathways. Nat. Rev. Mol. Cell Biol. 2002, 3:663-672.
15. García Z., Silio V., Marqués M., Cortés I., Kumar A., Hernandez C., Checa A.I., Serrano A., Carrera A.C. A PI3K activity-independent function of p85 regulatory subunit in control of mammalian cytokinesis. EMBO J. 2006, 25:4740-4751.
16. Hellyer N.J., Cheng K., Koland J.G. ErbB3 (HER3) interaction with the p85 regulatory subunit of phosphoinositide 3-kinase. Biochem. J. 1998, 333:757-763.
17. Inder K., Harding A., Plowman S.J., Philips M.R., Parton R.G., Hancock J.F. Activation of the MAPK module from different spatial locations generates distinct system outputs. Mol. Biol. Cell 2008, 19:4776-4784.
18. Johansson A., Driessens M., Aspenström P. The mammalian homologue of the Caenorhabditis elegans polarity protein PAR-6 is a binding partner for the Rho GTPases Cdc42 and Rac1. J.Cell Sci. 2000, 113:3267-3275.
19. Kandoth C., Schultz N., Cherniack A.D., Akbani R., Liu Y., Shen H., Robertson A.G., Pashtan I., Shen R., Benz C.C., et al. Integrated genomic characterization of endometrial carcinoma. Nature 2013, 497:67-73. Cancer Genome Atlas Research Network.
20. Kawashima T., Bao Y.C., Nomura Y., Moon Y., Tonozuka Y., Minoshima Y., Hatori T., Tsuchiya A., Kiyono M., Nosaka T., et al. Rac1 and a GTPase-activating protein, MgcRacGAP, are required for nuclear translocation of STAT transcription factors. J.Cell Biol. 2006, 175:937-946.
21. Koh W., Sachidanandam K., Stratman A.N., Sacharidou A., Mayo A.M., Murphy E.A., Cheresh D.A., Davis G.E. Formation of endothelial lumens requires a coordinated PKCepsilon-, Src-, Pak- and Raf-kinase-dependent signaling cascade downstream of Cdc42 activation. J.Cell Sci. 2009, 122:1812-1822.
22. Lagana A., Dorn J.F., De Rop V., Ladouceur A.M., Maddox A.S., Maddox P.S. A small GTPase molecular switch regulates epigenetic centromere maintenance by stabilizing newly incorporated CENP-A. Nat. Cell Biol. 2010, 12:1186-1193.
23. Lanning C.C., Ruiz-Velasco R., Williams C.L. Novel mechanism of the co-regulation of nuclear transport of SmgGDS and Rac1. J.Biol. Chem. 2003, 278:12495-12506.
24. Lutzky J., Bauer J., Bastian B.C. Dose-dependent, complete response to imatinib of a metastatic mucosal melanoma with a K642E KIT mutation. Pigment Cell Melanoma Res 2008, 21:492-493.
25. Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W., Harris P.L., Haserlat S.M., Supko J.G., Haluska F.G., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N.Engl. J. Med. 2004, 350:2129-2139.
26. McGlade C.J., Ellis C., Reedijk M., Anderson D., Mbamalu G., Reith A.D., Panayotou G., End P., Bernstein A., Kazlauskas A., et al. SH2 domains of the p85 alpha subunit of phosphatidylinositol 3-kinase regulate binding to growth factor receptors. Mol. Cell. Biol. 1992, 12:991-997.
27. Murga C., Zohar M., Teramoto H., Gutkind J.S. Rac1 and RhoG promote cell survival by the activation of PI3K and Akt, independently of their ability to stimulate JNK and NF-kappaB. Oncogene 2002, 21:207-216.
28. Ness R.B. Endometriosis and ovarian cancer: thoughts on shared pathophysiology. Am. J. Obstet. Gynecol. 2003, 189:280-294.
29. Oda K., Okada J., Timmerman L., Rodriguez-Viciana P., Stokoe D., Shoji K., Taketani Y., Kuramoto H., Knight Z.A., Shokat K.M., McCormick F. PIK3CA cooperates with other phosphatidylinositol 3'-kinase pathway mutations to effect oncogenic transformation. Cancer Res. 2008, 68:8127-8136.
30. Pandey A., Lazar D.F., Saltiel A.R., Dixit V.M. Activation of the Eck receptor protein tyrosine kinase stimulates phosphatidylinositol 3-kinase activity. J.Biol. Chem. 1994, 269:30154-30157.
31. Quayle S.N., Lee J.Y., Cheung L.W., Ding L., Wiedemeyer R., Dewan R.W., Huang-Hobbs E., Zhuang L., Wilson R.K., Ligon K.L., et al. Somatic mutations of PIK3R1 promote gliomagenesis. PLoS ONE 2012, 7:e49466.
32. Rodriguez-Viciana P., Warne P.H., Dhand R., Vanhaesebroeck B., Gout I., Fry M.J., Waterfield M.D., Downward J. Phosphatidylinositol-3-OH kinase as a direct target of Ras. Nature 1994, 370:527-532.
33. Stankiewicz T.E., Haaning K.L., Owens J.M., Jordan A.S., Gammon K., Bruns H.A., McDowell S.A. GTPase activating protein function of p85 facilitates uptake and recycling of the beta1 integrin. Biochem. Biophys. Res. Commun. 2010, 391:443-448.
34. Taniguchi C.M., Tran T.T., Kondo T., Luo J., Ueki K., Cantley L.C., Kahn C.R. Phosphoinositide 3-kinase regulatory subunit p85alpha suppresses insulin action via positive regulation of PTEN. Proc. Natl. Acad. Sci. USA 2006, 103:12093-12097.
35. Taniguchi C.M., Aleman J.O., Ueki K., Luo J., Asano T., Kaneto H., Stephanopoulos G., Cantley L.C., Kahn C.R. The p85alpha regulatory subunit of phosphoinositide 3-kinase potentiates c-Jun N-terminal kinase-mediated insulin resistance. Mol. Cell. Biol. 2007, 27:2830-2840.
36. Teramoto H., Coso O.A., Miyata H., Igishi T., Miki T., Gutkind J.S. Signaling from the small GTP-binding proteins Rac1 and Cdc42 to the c-Jun N-terminal kinase/stress-activated protein kinase pathway. A role for mixed lineage kinase 3/protein-tyrosine kinase 1, a novel member of the mixed lineage kinase family. J.Biol. Chem. 1996, 271:27225-27228.
37. Tolias K.F., Cantley L.C., Carpenter C.L. Rho family GTPases bind to phosphoinositide kinases. J.Biol. Chem. 1995, 270:17656-17659.
38. Tournier C., Whitmarsh A.J., Cavanagh J., Barrett T., Davis R.J. Mitogen-activated protein kinase kinase 7 is an activator of the c-Jun NH2-terminal kinase. Proc. Natl. Acad. Sci. USA 1997, 94:7337-7342.
39. Ward P.S., Patel J., Wise D.R., Abdel-Wahab O., Bennett B.D., Coller H.A., Cross J.R., Fantin V.R., Hedvat C.V., Perl A.E., et al. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell 2010, 17:225-234.
40. Yasuda S., Oceguera-Yanez F., Kato T., Okamoto M., Yonemura S., Terada Y., Ishizaki T., Narumiya S. Cdc42 and mDia3 regulate microtubule attachment to kinetochores. Nature 2004, 428:767-771.
41. Yu J., Zhang Y., McIlroy J., Rordorf-Nikolic T., Orr G.A., Backer J.M. Regulation of the p85/p110 phosphatidylinositol 3'-kinase: stabilization and inhibition of the p110alpha catalytic subunit by the p85 regulatory subunit. Mol. Cell. Biol. 1998, 18:1379-1387.
42. Zhang H., Gallo K.A. Autoinhibition of mixed lineage kinase 3 through its Src homology 3 domain. J.Biol. Chem. 2001, 276:45598-45603.
43. Zheng Y., Bagrodia S., Cerione R.A. Activation of phosphoinositide 3-kinase activity by Cdc42Hs binding to p85. J.Biol. Chem. 1994, 269:18727-18730.